学会発表（国際）
A randomized phase II study evaluating the use of prydoxine to prevent hand-foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer.
Yoshimura A, Iwata H, Hayashi T, Kobayashi N, Saito K, Tsuneizumi M, Sawaki M, Hattori M, Nakada T, Yokota I, Toyama T. A randomized phase II study evaluating the use of prydoxine to prevent hand-foot syndrome associated with capecitabine therapy for advanced or metastatic breast cancer. 2014 ASCO annual meeting, Chicago, IL, Jun 1, 2014. J Clin Oncol 32:5s, 2014 (suppl; abstr 9610).